Skip to main
  1. Stocks
  2. GeneDx Holdings Corp
  3. Forecast
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings is supported by strong demand in pediatric and rare-disease testing, with Q3 volume up 25% year over year and Q2 revenue of $114 million, while management and the analyst both frame the rare-disease end market as robust. Its long-term outlook is strengthened by a growing shift from exomes to genomes, an Infinity database built over 25 years with more than 1 million exomes/genomes, 80% share in its core medical geneticist call point, and new coverage wins such as Medi-Cal and Carelon that should improve reimbursement visibility. Near-term execution is uneven because of RCM and EMR onboarding and an ASP headwind, but the company’s leadership refresh, gross margin expansion potential, and multiple growth catalysts in 2026-2027 support the positive stance.

Bears say

GeneDx Holdings is facing a less attractive fundamental setup because management lowered its 2026 volume outlook to at least 28% from 30%+, and even with reaffirmed 2026 revenue of $475 million to $490 million, Q4’26 revenue of $135 million still came in below expectations. The bigger concern is reimbursement risk: the company estimated ~45% of revenue could be hit by a 15% CLFS price cut in 2027, creating an implied 6.75% revenue headwind and forcing cuts to revenue estimates for 2026, 2027, and 2028. Although it is investing in pediatricians, the NICU, and newborn screening, those opportunities add execution risk while 2027 adjusted net income fell to just $2 million from $15 million previously, underscoring margin and earnings pressure.

WGS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

WGS Analyst Forecast & Price Prediction

Get the latest WGS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in WGS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 5 analysts, WGS has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $79.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $79.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


WGS Analyst Forecast & Price Prediction

Get the latest WGS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in WGS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover WGS stock data and trends